Finasteride Side Effects: What the Data Actually Shows

Short answer: FDA trial data shows sexual side effects (decreased libido, erectile dysfunction, ejaculation changes) occur in roughly 2-4% of men on finasteride, higher than placebo but still uncommon, and these rates decline substantially with continued use. A smaller, genuinely debated body of research has also raised questions about persistent side effects after stopping and possible links to mood-related symptoms — an area where the scientific evidence is still actively contested, not settled in either direction. Here's what the actual data shows, without minimizing or overstating it.

This is a topic where getting the actual numbers right matters more than most — both because it's a common concern and because a lot of what circulates about it online isn't well-sourced. Here's what FDA trial data, postmarketing surveillance, and peer-reviewed research actually show.

What FDA Clinical Trials Found

Finasteride's original approval trials tracked side effects carefully, and the numbers are more modest than online discussion sometimes suggests — though real.

In year one of treatment:

Looking at these as a combined group — anyone reporting at least one sexual side effect — about 3.8% of men on finasteride reported something, compared to 2.1% on placebo. That's a statistically meaningful difference, but it also means the large majority of men in these trials didn't report any sexual side effect at all.

A separate, more sensitive measure: a self-administered questionnaire found subtler differences favoring placebo in three specific measures — sexual interest, erections, and perceived sexual problems — at 12 months. But when men were asked directly about overall satisfaction with their sex life, there was no significant difference between groups. This is worth sitting with: more granular self-report measures picked up something the broader adverse-event categories didn't fully capture, even though it didn't translate into an overall satisfaction difference.

These rates go down substantially over time. By year five of continued treatment, incidence of each of these effects had dropped to 0.3% or less. Separately, a large 4-year study of the related medication finasteride 5mg (used for prostate treatment, not hair loss) found no evidence that sexual side effects increase the longer someone stays on treatment — new reports actually decreased with more time on the medication.

Discontinuation due to side effects overall: just 1.4% of finasteride-treated men stopped due to a drug-related side effect of any kind in the original trials, compared to 1.6% of men on placebo — meaning drug-related discontinuation wasn't meaningfully different from the placebo group.

Do Side Effects Go Away After Stopping?

The FDA label states that resolution "occurred in men who discontinued therapy... and in most of those who continued therapy" — using the word "most," not a specific percentage.

At the same time, the FDA's own postmarketing surveillance section lists sexual dysfunction that continued after stopping — including erectile dysfunction, libido changes, ejaculation and orgasm-related issues — as an identified category of reported adverse reaction. Both things are true simultaneously: the trial data shows resolution is the typical outcome, and postmarketing reports include a smaller number of cases where symptoms were reported to persist.

On fertility specifically: some cases of reduced semen quality have been reported, but the label also notes normalization or improvement of semen quality has been reported after stopping — suggesting this particular effect does often reverse.

Post-Finasteride Syndrome: What the Evidence Actually Shows

"Post-finasteride syndrome" (PFS) is the term used to describe a cluster of persistent sexual, physical, and cognitive symptoms that some patients report continuing indefinitely after stopping finasteride — not resolving the way the trial data suggests is typical.

This is a genuinely contested area of the science, not a settled question in either direction, and it's worth understanding why.

A 2022 analysis of the World Health Organization's global adverse event database found a real statistical signal for suicidality and psychological adverse events among finasteride users, with stronger signals in younger patients and those treated specifically for hair loss (rather than prostate conditions). But the same researchers found something important: the signal was significantly stronger after 2012 specifically — the year PFS first received major media attention — which they explicitly flagged as consistent with "stimulated reporting" bias. In plain terms: once something gets public attention, more people who experience it report it, which can make a rare-but-real effect look more common in adverse-event databases than it actually is, independent of whether the underlying rate changed at all.

A 2025 study of FDA adverse event data reached a similar pattern: no meaningful signal for depression or suicidal ideation in reports from 2006-2011 (before PFS was widely known), but a clear signal appearing in 2013 onward — again, right after the public attention began. The researchers were direct about this limitation, writing that the increase "may be linked to heightened awareness... following the recognition of so-called PFS in 2012," rather than necessarily reflecting a true change in how often it happens.

International regulators have looked at this too, with genuinely mixed conclusions. Health Canada's review stated the evidence "could neither confirm nor deny a causal relationship" between finasteride and suicide-related risk — but still concluded there may be a link and updated their labeling as a precaution. The UK, EU, and Australian regulators have made similar precautionary label updates based on accumulating reports, without claiming the connection is proven.

What this means practically: the FDA label's postmarketing section does list depression and suicidal ideation as reported adverse reactions. The scientific question of whether finasteride causes this at a meaningful rate, versus whether increased public awareness led to increased reporting of something that was always happening at a similar baseline rate, remains genuinely unresolved in the research as of this writing.

If you're taking finasteride and experiencing depression, suicidal thoughts, or significant mood changes, this is worth discussing with a doctor promptly rather than waiting — regardless of whether the underlying cause turns out to be the medication.

Other Reported Side Effects

Non-sexual, non-psychiatric effects: Breast tenderness or enlargement, allergic-type reactions, and testicular pain were tracked in trials, and none occurred at rates meaningfully different from placebo.

Hypersensitivity reactions: Rash, itching, hives, and swelling of the lips, tongue, throat, or face have been reported after approval, though these appear to be uncommon.

Male breast cancer:This is listed in postmarketing data, but the FDA label itself states the relationship between long-term finasteride use and this risk is "currently unknown" — the case numbers in the studies that have looked at this are small (for example, 4 cases in a large prostate-treatment trial with none in the untreated comparison group, and just 1 case each in a separate trial's treatment and placebo groups), which isn't enough to draw a firm conclusion either way.

A Note on How to Read This Kind of Data

Several of the studies referenced above use FDA adverse event databases — systems where anyone (patients, doctors, or manufacturers) can voluntarily report a suspected side effect. These databases are genuinely useful for spotting potential safety signals early, but they have a well-known limitation: they can't establish that a medication caused a reported event, only that a statistical association or reporting pattern exists. Increased media attention on a topic reliably increases how often people report related symptoms, independent of whether the actual underlying rate changed — which is exactly the pattern researchers flagged around 2012 for finasteride specifically. That's not a reason to dismiss the signal, but it is a reason to treat it as an open question rather than a settled conclusion.

Frequently Asked Questions